Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026)
Surrozen (SRZN) recorded quarterly Total Non-Current Liabilities of $249.9 million in Q1 2026, up 43.69% quarter-over-quarter from $173.9 million in Q4 2025, and up 274.53% on a YoY basis from $66.7 million in Q1 2025.
Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Surrozen's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $249.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 274.53% year-over-year to $249.9 million; the TTM figure through Mar 2026 stood at $249.9 million (up 274.53% YoY), while the FY2025 annual figure was $173.9 million, up 149.03% from the prior year.
- Total Non-Current Liabilities was $249.9 million for Q1 2026 at Surrozen, up from $173.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $249.9 million in Q1 2026 to a low of $6.0 million in Q2 2024.
- Historically, Total Non-Current Liabilities has averaged $44.3 million across 5 years, with a median of $13.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slumped 39.44% in 2024, then surged 946.03% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $13.1 million in 2022, then tumbled by 38.74% to $8.0 million in 2023, then jumped by 769.83% to $69.8 million in 2024, then surged by 149.03% to $173.9 million in 2025, then surged by 43.69% to $249.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $249.9 million (Q1 2026), $173.9 million (Q4 2025), and $64.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 249.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 249.93 Mn |
| Dec 31, 2025 | 173.94 Mn |
| Sep 30, 2025 | 64.02 Mn |
| Jun 30, 2025 | 22.96 Mn |
| Mar 31, 2025 | 66.73 Mn |
| Dec 31, 2024 | 69.85 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 6.40 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 8.62 Mn |
| Mar 31, 2023 | 10.57 Mn |
| Dec 31, 2022 | 13.11 Mn |
| Sep 30, 2022 | 12.61 Mn |
| Jun 30, 2022 | 13.05 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 19.17 Mn |
| Sep 30, 2021 | 18.60 Mn |
| Jun 30, 2021 | 4.76 Mn |